Back to search

Article

Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysis

2017-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9c50f6cc-36ea-53cf-a2fe-128b1e19a89d
DOI
10.1016/s0168-8278(17)31967-0
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysisDOI 10.1016/s0168-8278(17)31967-0
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.Semantic proximity
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.Semantic proximity
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.Semantic proximity
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.Semantic proximity
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.Semantic proximity
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.Semantic proximity
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.Semantic proximity
Glecaprevir/Pibrentasvir: First Global Approval.Semantic proximity
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.Semantic proximity
Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.Semantic proximity
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.Semantic proximity
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.Semantic proximity
Select a neighboring publication to make it the new centre.